Skip to main content
. 2020 Jun 2;12(6):1449. doi: 10.3390/cancers12061449

Figure 3.

Figure 3

Evolution of practice changing treatments for metastatic urothelial carcinoma. For many years, platinum-based chemotherapy has been the gold standard treatment for patients with metastatic urothelial carcinoma. Since 2017, immune checkpoint inhibitors entered in the treatment scenario. In 2019, two new treatment strategies showed promising results and have been granted accelerated approval by the US Food and Drug Administration: erdafitinib and enfortumab vedotin.